From f259748f7094c84fc07dc0ac87d74540e8340e00 Mon Sep 17 00:00:00 2001 From: Teleo Agents Date: Wed, 6 May 2026 04:33:25 +0000 Subject: [PATCH] vida: extract claims from 2026-q1-psychopharmacology-glp1-psychiatric-review - Source: inbox/queue/2026-q1-psychopharmacology-glp1-psychiatric-review.md - Domain: health - Claims: 0, Entities: 0 - Enrichments: 3 - Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5) Pentagon-Agent: Vida --- ...competency-gap-primary-care-psychiatric-monitoring.md | 9 ++++++++- ...tric-worsening-42-percent-within-individual-design.md | 7 +++++++ ...2026-q1-psychopharmacology-glp1-psychiatric-review.md | 5 ++++- 3 files changed, 19 insertions(+), 2 deletions(-) rename inbox/{queue => archive/health}/2026-q1-psychopharmacology-glp1-psychiatric-review.md (97%) diff --git a/domains/health/glp1-prescribing-competency-gap-primary-care-psychiatric-monitoring.md b/domains/health/glp1-prescribing-competency-gap-primary-care-psychiatric-monitoring.md index 1c574d857..9faf6c48a 100644 --- a/domains/health/glp1-prescribing-competency-gap-primary-care-psychiatric-monitoring.md +++ b/domains/health/glp1-prescribing-competency-gap-primary-care-psychiatric-monitoring.md @@ -10,9 +10,16 @@ agent: vida sourced_from: health/2026-osmind-glp1-psychiatric-drugs-tonic-phasic.md scope: structural sourcer: Osmind -related: ["glp1-therapy-requires-nutritional-monitoring-infrastructure-but-92-percent-receive-no-dietitian-support", "healthcare AI creates a Jevons paradox because adding capacity to sick care induces more demand for sick care", "glp1-discontinuation-predicted-by-psychiatric-comorbidity-creating-access-adherence-trap", "glp1-eating-disorder-screening-gap-structural-capacity-not-clinical-knowledge", "glp1-psychiatric-effects-directionally-opposite-metabolic-versus-psychiatric-populations", "glp1-anhedonia-undermines-social-engagement-as-non-clinical-health-determinant", "glp1-atypical-anorexia-screening-gap-creates-invisible-high-risk-population", "glp1-harm-mediated-by-cultural-weight-stigma-not-pharmacology-alone"] +related: ["glp1-therapy-requires-nutritional-monitoring-infrastructure-but-92-percent-receive-no-dietitian-support", "healthcare AI creates a Jevons paradox because adding capacity to sick care induces more demand for sick care", "glp1-discontinuation-predicted-by-psychiatric-comorbidity-creating-access-adherence-trap", "glp1-eating-disorder-screening-gap-structural-capacity-not-clinical-knowledge", "glp1-psychiatric-effects-directionally-opposite-metabolic-versus-psychiatric-populations", "glp1-anhedonia-undermines-social-engagement-as-non-clinical-health-determinant", "glp1-atypical-anorexia-screening-gap-creates-invisible-high-risk-population", "glp1-harm-mediated-by-cultural-weight-stigma-not-pharmacology-alone", "glp1-prescribing-competency-gap-primary-care-psychiatric-monitoring", "glp1-anhedonia-tonic-receptor-occupancy-dose-dependent-reversible"] --- # Primary care prescribers of GLP-1s at therapeutic weight-loss doses lack psychiatric competency to monitor for CNS effects, creating structural risk of anhedonia in patients without psychiatric support GLP-1 receptors are densely distributed in VTA, nucleus accumbens, insula, and prefrontal cortex—psychiatric-relevant brain circuits. The drugs function as dopaminergic modulators, not just metabolic agents. However, psychiatrists are managing patients prescribed GLP-1s by primary care/endocrinology without understanding CNS mechanisms, dosing nuances, or psychiatric adverse effects. The competency gap creates structural risk: wrong prescriber (primary care optimizing for weight loss), wrong dose (therapeutic doses creating high tonic suppression), wrong monitoring (no psychiatric assessment for anhedonia). Primary care prescribers optimize for the measurable metric (weight loss, HbA1c) while externalizing the psychiatric cost. Osmind recommends: 'Psychiatrists should consider prescribing GLP-1s directly for SUD and mood disorders, not outsourcing to primary care.' The article identifies this as a structural misalignment where the prescribing system optimizes for one outcome while creating unmonitored harm in another domain. This is analogous to Belief 3's structural misalignment thesis: systems optimize for measurable proxies while externalizing costs to domains outside their competency. + + +## Extending Evidence + +**Source:** Psychopharmacology Institute Q1 2026 Review + +The Psychopharmacology Institute — a CME platform for practicing psychiatrists — now covers GLP-1 receptor agonists as emerging psychiatric pharmacology in quarterly clinical reviews. This signals that professional psychiatric education is actively incorporating GLP-1 into the psychiatric medication framework, moving beyond endocrinology-only prescribing. However, the review does not provide clinical screening protocols for psychiatrists evaluating patients already prescribed GLP-1s by other providers, indicating the competency gap persists at the protocol level despite conceptual recognition. diff --git a/domains/health/semaglutide-reduces-psychiatric-worsening-42-percent-within-individual-design.md b/domains/health/semaglutide-reduces-psychiatric-worsening-42-percent-within-individual-design.md index 52877cc3c..2ea466805 100644 --- a/domains/health/semaglutide-reduces-psychiatric-worsening-42-percent-within-individual-design.md +++ b/domains/health/semaglutide-reduces-psychiatric-worsening-42-percent-within-individual-design.md @@ -18,3 +18,10 @@ related: ["glp1-receptor-agonists-address-substance-use-disorders-through-mesoli # Semaglutide reduces worsening of depression, anxiety, and substance use disorder by 40-50% in people with pre-existing mental illness through within-individual comparison A Swedish national registry study published in Lancet Psychiatry (March 2026) used within-individual stratified Cox models to compare psychiatric outcomes during periods when the same person was ON versus OFF semaglutide. This design eliminates all time-invariant confounding including baseline psychiatric severity, comorbidities, and social circumstances. Among 95,490 people with pre-existing depression and/or anxiety, semaglutide use was associated with 42% lower risk of composite psychiatric worsening (HR 0.58). Specific outcomes: depression worsening HR 0.56 (44% reduction), anxiety worsening HR 0.62 (38% reduction), substance use disorder worsening HR 0.53 (47% reduction), and self-harm 47% reduction. Liraglutide showed weaker effects at 18% reduction (HR 0.82). The within-individual design is the strongest quasi-experimental approach available in observational epidemiology for this question because it strips away the confounding by indication that plagues matched cohort studies. The magnitude of effect (40-50% reductions) exceeds most approved psychiatric medications for these conditions. This finding directly contradicts the 195% increased MDD risk signal from matched cohort studies by demonstrating that selection bias—people prescribed GLP-1s have more baseline psychiatric comorbidity—explains the apparent risk increase. The FDA meta-analysis of 91 RCTs (107,910 patients) showing no increased psychiatric risk converges with this Swedish finding, while the matched cohort diverges due to methodological limitations. + + +## Supporting Evidence + +**Source:** Psychopharmacology Institute Q1 2026 Review citing 2026 national cohort study + +2026 national cohort study found semaglutide associated with 42% lower risk of worsening mental illness versus non-use periods in within-individual design. This reduced worsening of depression, anxiety, and substance use disorder. The Psychopharmacology Institute review explicitly notes these findings are observational and that randomized controlled trials are needed to confirm causality. diff --git a/inbox/queue/2026-q1-psychopharmacology-glp1-psychiatric-review.md b/inbox/archive/health/2026-q1-psychopharmacology-glp1-psychiatric-review.md similarity index 97% rename from inbox/queue/2026-q1-psychopharmacology-glp1-psychiatric-review.md rename to inbox/archive/health/2026-q1-psychopharmacology-glp1-psychiatric-review.md index 022ba36d7..c8127a51c 100644 --- a/inbox/queue/2026-q1-psychopharmacology-glp1-psychiatric-review.md +++ b/inbox/archive/health/2026-q1-psychopharmacology-glp1-psychiatric-review.md @@ -7,10 +7,13 @@ date: 2026-04-01 domain: health secondary_domains: [] format: article -status: unprocessed +status: processed +processed_by: vida +processed_date: 2026-05-06 priority: medium tags: [GLP-1, semaglutide, psychiatric-medications, FDA, suicidality, mental-health, professional-review, 2026] intake_tier: research-task +extraction_model: "anthropic/claude-sonnet-4.5" --- ## Content